3-Acetyl-1,2,3,4,8,9,10,11,12,13-decahydrocycloocta[b][1,4]diazepino[6,7,1-hi]indole | 422318-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-Acetyl-1,2,3,4,8,9,10,11,12,13-decahydrocycloocta[b][1,4]diazepino[6,7,1-hi]indole
• 英文别名: 1-(1,16-diazatetracyclo[8.8.1.02,9.014,19]nonadeca-2(9),10,12,14(19)-tetraen-16-yl)ethanone
• CAS: 422318-45-4
• 化学式: C₁₉H₂₄N₂O
• 分子量: 296.412
• InChiKey: XUIWLOANNKPQGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Acetyl-1,2,3,4,8,9,10,11,12,13-decahydrocycloocta[b][1,4]diazepino[6,7,1-hi]indole 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 1,2,3,4,8,9,10,11,12,13-Decahydrocycloocta[b][1,4]diazepino[6,7,1-hi]indole
  参考文献：
  名称：

  Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor

  摘要：

  Evaluation of selected compounds from our Corporate Compound Library in a human 5-HT2C receptor binding assay led to the discovery of WAY-629, a cyclohexyl[b][1,4]benzodiazepinoindole (K-i 56nM, E-max 90%), which is selective for the 5-HT2C receptor versus other serotonin receptor subtypes, and dopamine, histamine, adrenergic, and muscarinic receptors. In addition, WAY-629 was active in vivo in a rat model of feeding behavior. An SAR study based on WAY-629 led to compound 11 (K-i 13 nM, E-max 102%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.100
• 作为产物：
  描述：

  3,4-二氢-1H-苯并[e][1,4]二氮杂卓-2,5-二酮 在 盐酸 、 lithium aluminium tetrahydride 、 TEA 、 溶剂黄146 、 锌 、 sodium nitrite 作用下， 以 四氢呋喃 为溶剂， 反应 49.5h， 生成 3-Acetyl-1,2,3,4,8,9,10,11,12,13-decahydrocycloocta[b][1,4]diazepino[6,7,1-hi]indole
  参考文献：
  名称：

  Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor

  摘要：

  Evaluation of selected compounds from our Corporate Compound Library in a human 5-HT2C receptor binding assay led to the discovery of WAY-629, a cyclohexyl[b][1,4]benzodiazepinoindole (K-i 56nM, E-max 90%), which is selective for the 5-HT2C receptor versus other serotonin receptor subtypes, and dopamine, histamine, adrenergic, and muscarinic receptors. In addition, WAY-629 was active in vivo in a rat model of feeding behavior. An SAR study based on WAY-629 led to compound 11 (K-i 13 nM, E-max 102%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.100

文献信息

• Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
  申请人：Wyeth

  公开号：US20040229865A1

  公开（公告）日：2004-11-18

  This invention provides compounds of formula I having the structure 1 wherein: R 1 and R 2 are H, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO 2 -alkyl, —SO 2 —NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated, acyl, or aroyl; R 3 , R 4 are H, alkyl, cycloalkyl or —CH 2 -cycloalkyl; R 5 is H or alkyl; R 6 is H or alkyl; and wherein the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, as well as methods for using these compounds to treat central nervous system disorders, including obsessive -compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.

  本发明提供了式I的化合物，其结构为1其中：R1和R2为H、烷基、环烷基、烷氧基、卤素、氟代烷基、—CN、—NH—SO2-烷基、—SO2—NH-烷基、烷基酰胺、氨基、烷基氨基、二烷基氨基、氟代、酰基或芳酰基；R3、R4为H、烷基、环烷基或—CH2-环烷基；R5为H或烷基；R6为H或烷基；其中虚线表示可选的双键；或其药学上可接受的盐，以及使用这些化合物治疗中枢神经系统疾病的方法，包括强迫症、抑郁症、焦虑症、广泛性焦虑症、精神分裂症、偏头痛、睡眠障碍、进食障碍、肥胖症、癫痫和脊髓损伤。
• Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
  申请人：Wyeth

  公开号：US06759405B2

  公开（公告）日：2004-07-06

  This invention provides compounds of formula I having the structure wherein: R1 and R2 are H, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated, acyl, or aroyl; R3, R4 are H, alkyl, cycloalkyl or —CH2-cycloalkyl; R5 is H or alkyl; R6 is H or alkyl; and wherein the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, as well as methods for using these compounds to treat central nervous system disorders, including obsessive-compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.

  本发明提供了公式I的化合物，其结构为：其中：R1和R2为H，烷基，环烷基，烷氧基，卤素，氟化烷基，—CN，—NH—SO2-烷基，—SO2—NH-烷基，烷基酰胺，氨基，烷基氨基，二烷基氨基，氟化物，酰基或芳酰基；R3，R4为H，烷基，环烷基或—CH2-环烷基；R5为H或烷基；R6为H或烷基；其中虚线表示可选的双键；或其药学上可接受的盐。此外，本发明还提供了使用这些化合物治疗中枢神经系统疾病的方法，包括强迫症，抑郁症，焦虑症，广泛性焦虑症，精神分裂症，偏头痛，睡眠障碍，进食障碍，肥胖症，癫痫和脊髓损伤。
• US6759405B2
  申请人：——

  公开号：US6759405B2

  公开（公告）日：2004-07-06
• US7271162B2
  申请人：——

  公开号：US7271162B2

  公开（公告）日：2007-09-18
• [EN] CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES<br/>[FR] CYCLOALKYL[B][1,4]DIAZEPINO[6,7,1-HI]INDOLES ET DERIVES
  申请人：WYETH CORP

  公开号：WO2002036596A2

  公开（公告）日：2002-05-10

  This invention provides cycloalkyl[1,4] diazepino[6,7,1-hi] indole compounds of the formula (I): or a pharmaceutically acceptable salt thereof, as well as methods and pharmaceutical compositions utilizing them for the treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.